Since Warmuth-Metz et al. first reported CNC in 1999 [6], only 15 cases (excluding one case of cerebellar liponeurocytoma in the fourth ventricle [19]), have been reported [6–18]. CNC cases were slightly more common in females than in males (female:male = 9:6) and more common in adults than in children (adult: children = 12:3). The average age was 38 years (range: 7–70), and median age was 34 years. The clinical manifestations of CNC in the fourth ventricle are not specific. Similar to other tumours in the fourth ventricle, the clinical manifestations of CNC in the fourth ventricle are mainly related to the size of the tumour and its adjacent areas. The main clinical manifestations of fourth ventricle tumours are intracranial hypertension caused by obstructive hydrocephalus, such as headache, dizziness, malignant vomiting, blurred vision, and standing instability and ataxia caused by compression of the surrounding tissues, such as brain stem and cerebellum. In 15 CNC cases reported in the literature thus far (Table 1), the main clinical manifestations are still symptoms of intracranial hypertension, such as headache, nausea and vomiting, as well as papilledema-related symptoms (14/15, 93.3%), including headache in 10 cases (10/15, 66.7%), nausea and vomiting in 9 cases (9/15, 60.0%), diplopia or blurred vision in 2 cases (2/15, 13.3%), ataxia or gait instability in 4 cases (4/15, 26.7%), lower limb weakness in 2 cases(2/15, 13.3%), and altered taste, tinnitus, and vertigo in one case respectively. Obstructive hydrocephalus is the main clinical manifestation of intraventricular neurocytoma. In the 15 cases of CNC in the fourth ventricle, hydrocephalus occurred in 10 cases. The appearance of acute obstructive hydrocephalus can suddenly aggravate the patient’s condition, even cerebral hernia, which is one of the indications of acute extraventricular drainage. In addition, when the tumour bleeds, it may suddenly aggravate the patient’s symptoms.
MRI is the first choice for the diagnosis of CNS tumours. Our previous study [20] showed that CNS tumours in the lateral ventricle generally present mild low-intensity to equal-intensity signals on T1WI, whereas T2WI presents equal-intensity to high intensity signals. In both T1 and T2 weighted images, a low density may indicate haemorrhage, cysts, or calcification. After injection of an enhancer, the MRI showed notable enhancement of heterogeneity in the solid portion of the tumour. The tumours were mostly cystic and solid. Is there a similar imaging pattern in CNS tumours of the four ventricles? Through comparative analysis of 15 cases of CNS tumours in the four ventricles, we found that the imaging manifestations of CNS tumours in the four ventricles were similar to those in the lateral ventricle, and most of them were mainly cystic and solid, with calcification, haemorrhage, and cystic degeneration [6, 7, 10, 14]. The radiographic findings of our case were quite special. Obvious cystic and solid lesions were present in the four ventricles. The soap bubble appearance on T2WI (Fig. 1B) was similar to that of CNC in the lateral ventricle (Figs. 4A–4D) [20]. Owing to the rarity of CNC in the fourth ventricle, accurate imaging diagnosis of this disease is extremely difficult, and it should be differentiated from other diseases, including ependymoma, medulloblastoma, ependymoma, choroid plexus papilloma, and rosette-forming glioneuronal tumour [17, 21].
Postoperative pathology is helpful for the diagnosis of CNC. Under the microscope, the tumour cells were all small round cells, and some of them had perikaryotic halo or transparent cytoplasm. Moreover, island cell-free areas were present. Syn is a transmembrane glycoprotein that exists in the presynaptic vesicle of neurons. Syn positive expression is an important indicator of nerve cells and tumours, and it is one of the main molecular markers of CNC. NSE is a glycolytic enzyme located in the cytoplasm of neurons and can also be found in CNC, but it can exist in non-neural tumours and lacks relative neural specificity. In addition, neuronal nucleus (NeuN) and epithelial membrane antigen (EMA) are helpful for the diagnosis and differentiation of CNC. Glial fibrillary acidic protein (GFAP) is commonly found in glial cell tumours. GFAP is positive in some CNC, suggesting that tumour cells may originate from progenitor cells or stem cells with bi-directional differentiation in the paraventricular region. When Syn is uncertain, electron microscopy can be performed, but it is not the first choice for routine diagnosis. The Ki-67 marker index has been demonstrated to be the most important marker of potentially malignant behaviour in CNC. Söylemezoglu et al. [22] argued that CNC is atypical if the Ki-67 marker index is greater than or equal to 2%. Among the 15 CNC cases reported in the literature (among which 1 case did not provide immunohistochemical results), 12 cases were positive for Syn, 6 for NSE, 4 for Neun, and 3 for GFAP, and the rest were positive for NF, EMA, S-100, Vimrntin, Bcl-2, Olig-2, MAP2, and Calretinin. The Ki67 index ranged from 1–30%. Unlike Söylemezoglu et al. [22], other researchers did not diagnose the disease as atypical central neuroblastoma although Ki-67 was greater than 2% in some of the 15 cases probably because the diagnosis of atypical central neuroblastoma not only requires Ki-67 greater than 2% but also is related to whether the tumour is accompanied by microvascular proliferation, mitosis, and necrosis. It is characterized by elevated MIB labelling index (MIB-1 LI) more than 2% or 3% and/or accompanying histological atypia, such as infiltrative margins, increased mitosis, pleomorphism, endovascular proliferation, and necrosis [23, 24].
Microsurgical resection is the preferred treatment for CNC, which can be adjuvant to radiotherapy. In the 15 CNC cases reported in the literature, only12 (including the present report) provided complete treatment details (Table 1). In these 12 cases, 9 (75%) patients received treatment by surgery alone, 3 (25%) received both surgery and radiation therapy, and no one was treated with chemotherapy. With regard to surgery type, GTR was performed in 8 (66.7%) cases. Subtotal resection was performed in 4 (33.3%) cases, and only 3 cases underwent surgery. No recurrent cases were reported in the 15 cases.
Treatment via gross total resection is the gold standard. Although total tumour resection can obtain good prognosis and can minimize the recurrence rate, it is difficult to perform for CNC cases located in fourth ventricle because they are likely to be closely tied to the brain stem, must not importune tumour whole cutting, can take full or partial nephrectomy. CNC is sensitive to radiotherapy, but the advantages and disadvantages of radiotherapy should be weighed because of the low malignant degree of CNC [24–26]. Whether radiotherapy should be used in patients with total tumour resection remains controversial. Rades et al. [27] stated that adjuvant radiotherapy after total tumour resection does not improve local control and patient prognosis. At present, the following cases are considered to be radiotherapy [28, 29]: 1) gross tumour resection but Ki-67 > 2% or 3%, 2) tumour is pathologically atypical, and 3) unresectable, subtotal resection, and recurrent CNC. For patients with subtotal resection, radiotherapy can not only substantially reduce the recurrence rate of tumour but also reduce residual tissues. Currently, the recommended dose of radiotherapy is 54–60 Gy. If postoperative recurrence occurs, then surgery (or stereotactic radiotherapy) may still be the first choice. Schild et al. [25] reported a 5-year survival rate in 88% of patients receiving either fractionated radiotherapy or stereotactic radiosurgery after surgical resection and only 71% of patients without adjuvant radiotherapy. Rades et al. [27] reviewed 310 CNC cases retrospectively and found that partial resection combined with radiotherapy provided better local control compared with partial resection alone, although it did not improve overall survival. Warmut-Metz et al. [6] performed radiotherapy (50.4 Gy) on an incomplete resection of CNC in the fourth ventricle. They observed some regression of residual tumour tissues during follow up 4 months later. Cook et al. [8] performed radiotherapy on a patient with incomplete resection and disseminated spinal cord, and the residual tumour was remarkably improved and the disseminated spinal cord lesion disappeared. The evidence of chemotherapy for CNC is obviously inadequate relative to that of radiotherapy. Lee et al. [30] suggested that although chemotherapy cannot be used as a routine treatment for CNC, it can still be used as a remedial treatment. Temozolomide was also incorporated into the chemotherapy regimen of CNC. However, the chemotherapy of CNC still warrants further research and verification [31].
In conclusion, CNC in the fourth ventricle is a rare intracranial tumour that is difficult to diagnose preoperatively. However, it can be considered when cystic and solid lesions are present in the fourth ventricle, especially when the morphology is like a soap bubble. Surgery is the main treatment for CNC, and adjuvant radiotherapy can be considered for partial or subtotal resection cases with good prognosis. No recurrence of CNC of the fourth ventricle has been reported thus far.